Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 29;6(4):84.
doi: 10.3390/medsci6040084.

Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment

Richard E Kast  1
Affiliations

Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment

Richard E Kast. Med Sci (Basel). .

Abstract

During glioblastoma treatment, the pharmaceutical monoclonal antibody to vascular endothelial growth factor A, bevacizumab, has improved the quality of life and delayed progression for several months, but has not (or only marginally) prolonged overall survival. In 2017, several dramatic research papers appeared that are crucial to our understanding of glioblastoma vis-a-vis the mode of action of bevacizumab. As a consequence of these papers, a new, potentially more effective treatment protocol can be built around bevacizumab. This is the ADZT regimen, where four old drugs are added to bevacizumab. These four drugs are apremilast, marketed to treat psoriasis, dapsone, marketed to treat Hansen's disease, zonisamide, marketed to treat seizures, and telmisartan, marketed to treat hypertension. The ancillary attributes of each of these drugs have been shown to augment bevacizumab. This paper details the research data supporting this contention. Phase three testing of AZDT addition to bevacizumab is required to establish safety and effectiveness before general use.

Keywords: ADZT regimen; TNF-alpha; apremilast; bevacizumab; cAMP; dapsone; glioblastoma; telmisartan; zonisamide.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., Colman H., Chakravarti A., Pugh S., Won M., et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 2014;370:699–708. doi: 10.1056/NEJMoa1308573. - DOI - PMC - PubMed
    1. Gramatzki D., Roth P., Rushing E.J., Weller J., Andratschke N., Hofer S., Korol D., Regli L., Pangalu A., Pless M., et al. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: An epidemiological study. Ann. Oncol. 2018;29:1431–1436. doi: 10.1093/annonc/mdy106. - DOI - PubMed
    1. Badruddoja M.A., Pazzi M., Sanan A., Schroeder K., Kuzma K., Norton T., Scully T., Mahadevan D., Ahmadi M.M. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. Cancer Chemother. Pharmacol. 2017;80:715–721. doi: 10.1007/s00280-017-3405-7. - DOI - PubMed
    1. Peters K.B., Lipp E.S., Miller E., Herndon J.E., 2nd, McSherry F., Desjardins A., Reardon D.A., Friedman H.S. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. J. Neurooncol. 2017;137:349–356. doi: 10.1007/s11060-017-2724-1. - DOI - PubMed
    1. Wick W., Gorlia T., Bendszus M., Taphoorn M., Sahm F., Harting I., Brandes A.A., Taal W., Domont J., Idbaih A., et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N. Engl. J. Med. 2017;377:1954–1963. doi: 10.1056/NEJMoa1707358. - DOI - PubMed